Anti-ATG4C Antibody (5V732) is a Rabbit antibody targeting ATG4C. Anti-ATG4C Antibody (5V732) can be used in WB,IHC-P,IHC-Fr,IF,ICC/IF.

IgG

5V732

Human

1. Paraformaldehyde-fixed, paraffin embedded Human Testicles; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with ATG4C Monoclonal Antibody, Unconjugated (TMAB-02921) at 1: 200 overnight at 4°C, followed by conjugation to the Goat Anti-Rabbit IgG H&L Secondary Antibody-HRP and DAB staining.
2. Paraformaldehyde-fixed, paraffin embedded Human Skeletal muscle; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with ATG4C Monoclonal Antibody, Unconjugated (TMAB-02921) at 1: 200 overnight at 4°C, followed by conjugation to the Goat Anti-Rabbit IgG H&L Secondary Antibody-HRP and DAB staining.
3. Paraformaldehyde-fixed, paraffin embedded Human Heart; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with ATG4C Monoclonal Antibody, Unconjugated (TMAB-02921) at 1: 200 overnight at 4°C, followed by conjugation to the Goat Anti-Rabbit IgG H&L Secondary Antibody-HRP and DAB staining.
4. 25 μg total protein per lane of various lysates (see on figure) probed with ATG4C monoclonal antibody, unconjugated (TMAB-02921) at 1: 2000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r. T. for 60 min.
5. 4% Paraformaldehyde-fixed Hela (H) cell; Triton X-100 at r. T. for 20 min; Antibody incubation with (ATG4C) monoclonal Antibody, unconjugated (TMAB-02921) 1:100, 90 min at 37°C; followed by conjugated Goat Anti-Rabbit IgG antibody (green) at 37°C for 90 min, DAPI (blue) was used to stain the cell nuclei. PBS instead of the primary antibody was used as the blank control.

WB: 1:500-2000; IHC-P: 1:50-200; IHC-Fr: 1:50-200; IF: 1:50-200; ICC/IF: 1:50-200

Monoclonal

A synthesized peptide: human ATG4C

Human

ATG4C

Cysteine protease ATG4C

Cysteine protease required for autophagy, which cleaves the C-terminal part of either MAP1LC3, GABARAPL2 or GABARAP, allowing the liberation of form I. A subpopulation of form I is subsequently converted to a smaller form (form II). Form II, with a revealed C-terminal glycine, is considered to be the phosphatidylethanolamine (PE)-conjugated form, and has the capacity for the binding to autophagosomes.